The sixth international RASopathies symposium: Precision medicine-From promise to practice

Karen W Gripp¹, Lisa Schill², Lisa Schoyer², Beth Stronach², Anton M Bennett³, Susan Blaser⁴, Amanda Brown⁵, Rebecca Burdine⁶, Emma Burkitt-Wright⁷, Pau Castel⁸, Sandra Darilek⁹, Alwyn Dias¹⁰, Tuesdi Dyer¹¹, Michelle Ellis², Gregg Erickson¹², Bruce D Gelb^{13

14}, Tamar Green¹⁵, Andrea Gross¹⁶, Alan Ho¹⁷, James Lloyd Holder Jr⁹, Shin-Ichi Inoue¹⁸, Angie C Jelin¹⁹, Annie Kennedy²⁰, Richard Klein²¹, Maria I Kontaridis²², Pilar Magoulas⁹, Darryl B McConnell²³, Frank McCormick⁸, Benjamin G Neel²⁴, Carlos E Prada²⁵, Katherine A Rauen²⁶, Amy Roberts^{27

28}, Pablo Rodriguez-Viciana²⁹, Neal Rosen¹⁷, Gavin Rumbaugh³⁰, Anna Sablina³¹, Maja Solman³², Marco Tartaglia³³, Angelica Thomas³⁴, William C Timmer¹⁶, Kartik Venkatachalam³⁵, Karin S Walsh³⁶, Pamela L Wolters³⁷, Jae-Sung Yi³, Martin Zenker³⁸, Nancy Ratner²⁵

Affiliations

¹ Al duPont Hospital for Children, Wilmington, Delaware.
² RASopathies Network USA, Altadena, California.
³ Yale University School of Medicine, New Haven, Connecticut.
⁴ Hospital for Sick Children, Toronto, Ontario, Canada.
⁵ Noonan Syndrome Foundation, Farmington, Connecticut.
⁶ Princeton University, Princeton, New Jersey.
⁷ Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust and University of Manchester, Manchester, UK.
⁸ UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
⁹ Baylor College of Medicine, Houston, Texas.
¹⁰ Bridge Group Consulting, Morristown, New Jersey.
¹¹ CFC International, Saint Petersburg, Florida.
¹² Neurofibromatosis Network, Rochester, Minnesota.
¹³ Department of Pediatrics, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁴ Department of Genetics and Genomic Sciences, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁵ Stanford University, Stanford, California.
¹⁶ National Cancer Institute, Bethesda, Maryland.
¹⁷ Memorial Sloan Kettering Cancer Center, New York, New York.
¹⁸ Tohoku University School of Medicine, Sendai, Miyagi, Japan.
¹⁹ Johns Hopkins Hospital, Baltimore, Maryland.
²⁰ Parent Project Muscular Dystrophy, Hackensack, New Jersey.
²¹ Parent Liaison, FDA, Bethesda, Maryland.
²² Masonic Medical Research Institute, Utica, New York.
²³ Boehringer-Ingelheim Regional Center Vienna, Vienna, Austria.
²⁴ Perlmutter Cancer Center and NYU School of Medicine, NYU Langone Health, New York, New York.
²⁵ Cincinnati Children's Hospital Medical Center and University of Cincinnati, School of Medicine, Cincinnati, Ohio.
²⁶ Department of Pediatrics, Division of Genomic Medicine, University of California Davis, Sacramento, California.
²⁷ Department of Cardiology, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts.
²⁸ Department of Pediatrics, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts.
²⁹ UCL Cancer Institute, London, UK.
³⁰ The Scripps Research Institute, Jupiter, Florida.
³¹ VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.
³² Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, The Netherlands.
³³ Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù-IRCCS, Rome, Italy.
³⁴ Costello Syndrome Family Network, Woodinville, Washington.
³⁵ McGovern Medical School, University of Texas Health Science Center, Houston, Texas.
³⁶ Children's National Hospital & The George Washington School of Medicine, Washington, District of Columbia.
³⁷ Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.
³⁸ University Hospital Magdeburg, Institute of Human Genetics, Magdeburg, Germany.

PMID: 31825160
PMCID: PMC7021559
DOI: 10.1002/ajmg.a.61434

The sixth international RASopathies symposium: Precision medicine-From promise to practice

Karen W Gripp et al. Am J Med Genet A. 2020 Mar.

. 2020 Mar;182(3):597-606.

doi: 10.1002/ajmg.a.61434. Epub 2019 Dec 11.

Authors

Affiliations

¹ Al duPont Hospital for Children, Wilmington, Delaware.
² RASopathies Network USA, Altadena, California.
³ Yale University School of Medicine, New Haven, Connecticut.
⁴ Hospital for Sick Children, Toronto, Ontario, Canada.
⁵ Noonan Syndrome Foundation, Farmington, Connecticut.
⁶ Princeton University, Princeton, New Jersey.
⁷ Manchester Centre for Genomic Medicine, Manchester University NHS Foundation Trust and University of Manchester, Manchester, UK.
⁸ UCSF, Helen Diller Family Comprehensive Cancer Center, San Francisco, California.
⁹ Baylor College of Medicine, Houston, Texas.
¹⁰ Bridge Group Consulting, Morristown, New Jersey.
¹¹ CFC International, Saint Petersburg, Florida.
¹² Neurofibromatosis Network, Rochester, Minnesota.
¹³ Department of Pediatrics, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁴ Department of Genetics and Genomic Sciences, Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, New York.
¹⁵ Stanford University, Stanford, California.
¹⁶ National Cancer Institute, Bethesda, Maryland.
¹⁷ Memorial Sloan Kettering Cancer Center, New York, New York.
¹⁸ Tohoku University School of Medicine, Sendai, Miyagi, Japan.
¹⁹ Johns Hopkins Hospital, Baltimore, Maryland.
²⁰ Parent Project Muscular Dystrophy, Hackensack, New Jersey.
²¹ Parent Liaison, FDA, Bethesda, Maryland.
²² Masonic Medical Research Institute, Utica, New York.
²³ Boehringer-Ingelheim Regional Center Vienna, Vienna, Austria.
²⁴ Perlmutter Cancer Center and NYU School of Medicine, NYU Langone Health, New York, New York.
²⁵ Cincinnati Children's Hospital Medical Center and University of Cincinnati, School of Medicine, Cincinnati, Ohio.
²⁶ Department of Pediatrics, Division of Genomic Medicine, University of California Davis, Sacramento, California.
²⁷ Department of Cardiology, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts.
²⁸ Department of Pediatrics, Division of Genetics, Boston Children's Hospital, Boston, Massachusetts.
²⁹ UCL Cancer Institute, London, UK.
³⁰ The Scripps Research Institute, Jupiter, Florida.
³¹ VIB-KU Leuven Center for Cancer Biology, Leuven, Belgium.
³² Hubrecht Institute-KNAW and University Medical Center Utrecht, Utrecht, The Netherlands.
³³ Genetics and Rare Diseases Research Division, Ospedale Pediatrico Bambino Gesù-IRCCS, Rome, Italy.
³⁴ Costello Syndrome Family Network, Woodinville, Washington.
³⁵ McGovern Medical School, University of Texas Health Science Center, Houston, Texas.
³⁶ Children's National Hospital & The George Washington School of Medicine, Washington, District of Columbia.
³⁷ Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland.
³⁸ University Hospital Magdeburg, Institute of Human Genetics, Magdeburg, Germany.

PMID: 31825160
PMCID: PMC7021559
DOI: 10.1002/ajmg.a.61434

Abstract

The RASopathies are a group of genetic disorders that result from germline pathogenic variants affecting RAS-mitogen activated protein kinase (MAPK) pathway genes. RASopathies share RAS/MAPK pathway dysregulation and share phenotypic manifestations affecting numerous organ systems, causing lifelong and at times life-limiting medical complications. RASopathies may benefit from precision medicine approaches. For this reason, the Sixth International RASopathies Symposium focused on exploring precision medicine. This meeting brought together basic science researchers, clinicians, clinician scientists, patient advocates, and representatives from pharmaceutical companies and the National Institutes of Health. Novel RASopathy genes, variants, and animal models were discussed in the context of medication trials and drug development. Attempts to define and measure meaningful endpoints for treatment trials were discussed, as was drug availability to patients after trial completion.

Keywords: Costello syndrome; Noonan syndrome; RASopathy; cardio-facio-cutaneous syndrome; kinases; neurofibromatosis.

PubMed Disclaimer

Conflict of interest statement

CONFLICTOF INTEREST

The authors do not declare a conflict of interest in regard to this manuscript.

References

1. Acquadro C, Berzon R, Dubois D, Leidy NK, Marquis P, Revicki D, … PRO Harmonization Group. (2003). Incorporating the patient’s perspective into drug development and communication: An ad hoc task force report of the patient-reported outcomes (PRO) harmonization group meeting at the Food and Drug Administration. Value in Health, 6, 522–531. 10.1046/j.1524-4733.2003.65309.x - DOI - PubMed
1. Andelfinger G, Marquis C, Raboisson MJ, Théoret Y, Waldmüller S, Wiegand G,… Hofbeck M. (2019). Hypertrophic cardiomyopathy in Noonan syndrome treated by MEK-inhibition. Journal of the American College of Cardiology, 73, 2237–2239. 10.1016/jjacc.2019.01.066 - DOI - PMC - PubMed
1. Araki T, Mohi MG, Ismat FA, Bronson RT, Williams IR, Kutok JL,… Neel BG (2004). Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nature Medicine, 10, 849–857. 10.1038/nm1084 - DOI - PubMed
1. Biard JM, Steenhaut P, Bernard P, Race V, & Sznajer Y. (2019). Antenatal diagnosis of cardio-facio-cutaneous syndrome: Prenatal characteristics and contribution of fetal facial dysmorphic signs in utero. European Journal of Obstetrics & Gynecology, 240, 232–241. 10.1016/j.ejogrb.2019.06.035 - DOI - PubMed
1. Castel P, Cheng A, Cuevas-Navarro A, Everman DB, Papageorge AG, Simanshu DK,… McCormick F. (2019). RIT1 oncoproteins escape LZTR1-mediated proteolysis. Science, 363, 1226–1230. 10.1126/science.aav1444 - DOI - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The sixth international RASopathies symposium: Precision medicine-From promise to practice

Affiliations

The sixth international RASopathies symposium: Precision medicine-From promise to practice

Authors

Affiliations

Abstract

Conflict of interest statement

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources